These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25289928)

  • 1. Role of osteocytes in multiple myeloma bone disease.
    Delgado-Calle J; Bellido T; Roodman GD
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):407-13. PubMed ID: 25289928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption.
    Kitaura H; Marahleh A; Ohori F; Noguchi T; Shen WR; Qi J; Nara Y; Pramusita A; Kinjo R; Mizoguchi I
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
    Liu H; He J; Bagheri-Yarmand R; Li Z; Liu R; Wang Z; Bach DH; Huang YH; Lin P; Guise TA; Gagel RF; Yang J
    Nat Commun; 2022 Jun; 13(1):3684. PubMed ID: 35760800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
    Front Immunol; 2018; 9():2467. PubMed ID: 30410490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
    Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
    Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.
    Giuliani N; Ferretti M; Bolzoni M; Storti P; Lazzaretti M; Dalla Palma B; Bonomini S; Martella E; Agnelli L; Neri A; Ceccarelli F; Palumbo C
    Leukemia; 2012 Jun; 26(6):1391-401. PubMed ID: 22289923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanisms of myeloma-induced bone disease].
    Abe M
    Clin Calcium; 2016 May; 26(5):699-706. PubMed ID: 27117615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocyte control of osteoclastogenesis.
    O'Brien CA; Nakashima T; Takayanagi H
    Bone; 2013 Jun; 54(2):258-63. PubMed ID: 22939943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
    Allison H; Holdsworth G; McNamara LM
    BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations.
    Kennedy OD; Herman BC; Laudier DM; Majeska RJ; Sun HB; Schaffler MB
    Bone; 2012 May; 50(5):1115-22. PubMed ID: 22342796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.
    Yan Y; Wang L; Ge L; Pathak JL
    Curr Osteoporos Rep; 2020 Feb; 18(1):67-80. PubMed ID: 31953640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of bone destruction in multiple myeloma.
    Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteocytes and Paget's Disease of Bone.
    Tenshin H; Delgado-Calle J; Windle JJ; Roodman GD; Chirgwin JM; Kurihara N
    Curr Osteoporos Rep; 2024 Apr; 22(2):266-272. PubMed ID: 38457001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteocyte-driven bone remodeling.
    Bellido T
    Calcif Tissue Int; 2014 Jan; 94(1):25-34. PubMed ID: 24002178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
    Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
    Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
    Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
    PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
    Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.
    Pathak JL; Bravenboer N; Klein-Nulend J
    Front Endocrinol (Lausanne); 2020; 11():405. PubMed ID: 32733380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteocyte regulation of bone mineral: a little give and take.
    Atkins GJ; Findlay DM
    Osteoporos Int; 2012 Aug; 23(8):2067-79. PubMed ID: 22302104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.